Genfleet Therapeutics (Shanghai), Inc.
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-08-23
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genfleet.com
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients with Pre-cachexia or Cachexia
- Conditions
- Cancer Cachexia
- Interventions
- Drug: GFS202A injection
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06898255
- Locations
- 🇨🇳
Sun-Yat Sen university cancer center, Guangzhou, Guangdong, China
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 390
- Registration Number
- NCT06500676
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06375733
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning, China
🇨🇳Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou, China
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05934513
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Conditions
- Advance Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05756153
- Locations
- 🇮🇹
IRCCS Centro di Riferimento Oncologico, Aviano, Friuli-Venezia Giulia, Italy
🇪🇸Virgen del Rocio University Hospital, Sevilla, Spain
🇪🇸Hospital Regional Universitario de Malaga,Oncology Dept, Málaga, Spain
A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
- Conditions
- NSCLC, Stage III
- Interventions
- Radiation: Thoracic Radiation Therapy (TRT)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05386888
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT04914286
- Locations
- 🇨🇳
Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
🇨🇳Shang hai east hospital, Shanghai, Shanghai, China
🇦🇺Linear Clinical Research Ltd, Perth, Western Australia, Australia